A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma
Status:
Withdrawn
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of TAC-101 after
Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable
hepatocellular carcinoma (HCC) who are being scheduled for TACE.